DCZ0415
CAS No. 2242470-43-3
DCZ0415 ( —— )
产品货号. M22920 CAS No. 2242470-43-3
DCZ0415 induces antimyeloma activity in vitro, in vivo and in primary cells of drug-resistant myeloma patients. DCZ0415 is a potent TRIP13 inhibitor that can impair the repair of non-homologous end junctions and inhibit NF-κB activity.DCZ0415 (10, 20 μM; 72 hours) showed a marked reduction in colony formation, indicating that it inhibited cell proliferation.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥575 | 有现货 |
|
5MG | ¥956 | 有现货 |
|
10MG | ¥1604 | 有现货 |
|
25MG | ¥3540 | 有现货 |
|
50MG | ¥5233 | 有现货 |
|
100MG | ¥7444 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称DCZ0415
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述DCZ0415 induces antimyeloma activity in vitro, in vivo and in primary cells of drug-resistant myeloma patients. DCZ0415 is a potent TRIP13 inhibitor that can impair the repair of non-homologous end junctions and inhibit NF-κB activity.DCZ0415 (10, 20 μM; 72 hours) showed a marked reduction in colony formation, indicating that it inhibited cell proliferation.
-
产品描述DCZ0415 induces antimyeloma activity in vitro, in vivo and in primary cells of drug-resistant myeloma patients. DCZ0415 is a potent TRIP13 inhibitor that can impair the repair of non-homologous end junctions and inhibit NF-κB activity.DCZ0415 (10, 20 μM; 72 hours) showed a marked reduction in colony formation, indicating that it inhibited cell proliferation. DCZ0415 (1.25-40 μM; 72 hours) caused a significant dose-dependent reduction in MM cell viability. DCZ0415 (10, 20 μM; 24-72 hours) showed a dose-dependent relationship between DCZ0415 treatment and apoptotic cell death. DCZ0415 (10, 20 μM; 24 hours) induced massive accumulation in G0 / G1 MM cells. DCZ0415 (10 μM; 48 hours) can reduce the protein levels of phosphorylated (p) -iκBα and phosphorylated (p) -NF-κB in MM cells. The IC50 of DCZ0415 in CalcuSyn in MM cell line is 1.0–10 μM. DCZ0415 exerts a cytotoxic effect by inhibiting the synthesis of DNA 288 in MM cells.DCZ0415, was confirmed to bind TRIP13 using pull-down, nuclear magnetic resonance spectroscopy, and surface plasmon resonance-binding assays.?DCZ0415 induced antimyeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant patients with myeloma.?The inhibitor impaired nonhomologous end joining repair and inhibited NF-κB activity.?Moreover, combining DCZ0415 with the multiple myeloma chemotherapeutic melphalan or the HDAC inhibitor panobinostat induced synergistic antimyeloma activity.?Therefore, targeting TRIP13 may be an effective therapeutic strategy for multiple myeloma, particularly refractory or relapsed multiple myeloma.?
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体TRIP13
-
研究领域——
-
适应症——
化学信息
-
CAS Number2242470-43-3
-
分子量356.42
-
分子式C23H20N2O2
-
纯度>98% (HPLC)
-
溶解度DMSO:62.5 mg/mL (175.35 mM; Need ultrasonic)
-
SMILESO=C1N(C2=CC=C(CC3=CC=NC=C3)C=C2)C(C4C5C(C6)C6C(C=C5)C14)=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Wang Y, et al. A Small Molecule Inhibitor Targeting TRIP13 suppresses multiple myeloma progression. Cancer Res. 2019 Nov 15. pii: canres.3987.2018.
产品手册
关联产品
-
2-Iminothiolane HCl
2-Iminothiolane HCl is a useful RNA-protein crosslinking reagent and an effective thiolation reagent for the introduction of sulphydryl groups into oligosaccharides.
-
Salvianan
Salviane exhibits the most potent cytotoxicity with a CD50 range of 30.4-39.5 microM against HeLa (cervical epitheloid carcinoma), HepG2 (hepatocellular carcinoma), and OVCAR-3 (ovarian adenocarcinoma) cell lines in a dose-dependent manner.
-
CycLuc1
CycLuc1 is a brain penetrant luciferase substrate.